Integrated BioTherapeutics, Inc.

Integrated BioTherapeutics, Inc. develops biotechnology solutions focused on advanced vaccines and therapeutic antibodies to address emerging infectious diseases. Founded in 2005 and headquartered in Rockville, US, Integrated BioTherapeutics, Inc. specializes in innovative therapies for infectious diseases.

The company raised USD 3. 9 mn in venture funding from Novo Holdings on January 6, 2020, which represents their total amount raised. The company specializes in the development of advanced biotechnology solutions, focusing on novel vaccines and therapeutic antibodies aimed at combating emerging infectious diseases. Their core offerings include macaque or human-derived monoclonal antibodies (mAbs) and engineered fusion mAbs with specific host-cell targeting capabilities.

Additionally, they produce single or multi-component adjuvanted vaccines for broad-spectrum neutralization against various viral and antibiotic-resistant bacterial pathogens, serving healthcare institutions, pharmaceutical companies, and research laboratories in North America and Europe. Integrated BioTherapeutics, Inc. generates revenue through partnerships and collaborations with biotech firms, research institutions, and healthcare providers, often involving licensing of their proprietary technologies. They engage in B2B transactions with pricing tailored to partners and clients, which may include upfront payments and milestone-based royalties linked to product development and commercialization.

The company plans to leverage the recent funding of USD 3. 9 mn to enhance its product development capabilities and expand into new markets. This includes designing and launching new vaccines and therapeutic antibodies aimed at combating infectious diseases, with a focus on expanding their presence in European and Asian markets by 2023.